Hologic Set to Go Private in Massive $18.3 Billion Deal with Backing from Blackstone and TPG
In a significant move within the healthcare sector, Blackstone and TPG have announced a plan to take Hologic private in a deal valued at approximately $18.3 billion. This acquisition marks one of the largest transactions in healthcare take-privates for the year.
Details of the Acquisition
Under the terms of the agreement, both Blackstone and TPG will acquire Hologic shares at a price of $76 each. This offer represents a premium of nearly 6% over Hologic’s last closing price.
- Deal Value: $18.3 billion
- Price per Share: $76 in cash
- Premium: Nearly 6% above the last closing price
In addition to the cash payment, shareholders of Hologic may also receive a non-tradable right to earn up to $3 per share. This contingent payment is based on meeting specific global revenue targets for Hologic’s breast health business during the fiscal years 2026 and 2027. Consequently, the total potential payout could reach $79 per share.
Market Reaction and Company Overview
Following the announcement, Hologic shares experienced an increase of over 4% in premarket trading, although trading was briefly halted during this period. Hologic is renowned for its dedication to women’s health diagnostics, focusing on breast and cervical cancer screenings and infectious disease testing.
- Specialization: Women’s health diagnostics
- Products: Cancer screening and infectious disease tests
Despite consistent growth in its molecular diagnostics segment, Hologic has noted ongoing challenges in the breast health area. The deal is anticipated to be finalized in the first half of 2026, marking a new chapter for the company under private ownership.
